

several workers [58–61]. Only a proportion of the colon will be usable for drug delivery, unless prepared by irrigation, and the useful sites will generally include the cecum and ascending and transverse colon. The length of time available for drug release in these regions of the gut, and the influence of formulation variables (size, shape, and density) on transit in “normal” and pathophysiological conditions, is therefore of great interest to pharmaceutical scientists. There are conflicting values in the literature regarding transit from cecum to splenic flexure; for example, in a study quantifying the change in geometric center in normal and slow transit, the value was approximately 15 h in normal subjects and 52 h in patients with slow colonic transit [62].

Gamma scintigraphy was used to compare the colonic transit rate of different sizes of nondisintegrating radiolabeled model dosage forms in healthy subjects. In the first study, colonic transit of radiolabeled capsules, volume 0.3–1.8 cm³ and density 0.7–1.5 g/cm³, were monitored in 18 healthy subjects. The capsules were administered after an overnight fast and entered the colon, on an average, 5 h after dosing. Transit rates through the proximal colon were independent of capsule density. Effects due to capsule volume were small compared to intersubject variations in transit rates. Within 10 h of entering the colon, 80% of the units had reached the splenic flexure [63].

By administering both sizes of formulation simultaneously, a better discrimination of relative transit of the two phases can be made. In a cohort of 22 healthy young volunteers, an enteric-coated capsule was administered, which contained tablets ([^{99m}Tc]-labeled; 5 or 8.4 mm in diameter) together with pellets ([¹¹¹In]-labeled 0.2 mm ion-exchange resin particles). The unit delivered the radiopharmaceuticals simultaneously to the ileocecal junction [64]. Under controlled conditions, no difference was observed between the rate of transit through the ascending colon of 0.2 mm particles versus 5 mm tablets or 0.2 mm particles versus 8.4 mm tablets. The mean period of residence of 50% of the administered 0.2 mm particles in the ascending colon was 11.0 ± 4.0 h.

Adkin and colleagues compared transit of 3, 6, and 12 mm nondisintegrating [¹¹¹In]-labeled tablets in eight healthy male volunteers. The transit of tablets through the ileocecal junction was unaffected by tablet size. All tablets entered into the colon as a bolus. The 3 and 6 mm tablets were retained in the ascending colon for the longest period of time [65].

21.5.2

Time of Dosing

The time of dosing is an important parameter with regard to the whole-gut transit of nondisintegrating formulations. Sathyan and colleagues [66] have noted that an analysis of 1163 administrations of OROS devices showed a bimodal distribution clustered at 12 and 36 h following nighttime dosing and 24 and 48 h after morning dosing. After nighttime dosing, a monolithic device will be propelled forward during the strong contractile activity on waking and rising, but may not move far enough to be excreted. Our own data show that, subsequent to the mass movement in the first hour of rising, propulsive movements are weak until sometime after the lunchtime meal has been ingested [67].

21.5.3

Modulating Colonic Water

In our early attempts at producing models of diarrheal predominant disease, it was found that the administration of the laxative lactulose provided a useful and reversible simulation of altered colonic hydrodynamics such as might be seen in colitis. Lactulose is used therapeutically to manage a number of conditions including hepatic encephalopathy, constipation, and salmonellosis. This semisynthetic disaccharide is neither metabolized nor absorbed in the normal small intestine, but may undergo bacterial fermentation in the colon to short-chain fatty acids and gases. Major consequences include a fall in pH and a change in the composition and metabolic activity of the colonic flora [68]. The changes provoked by lactulose are sensitive to fiber supplementation [69] and can be reversed by codeine [70].

In the experiments with enteric-coated tablet plus pellet preparations [64], a second leg was conducted in which a preparation containing 5 mm tablets and 0.2 mm resin was administered after laxative treatment. Following lactulose dosing, there was a significant acceleration in colonic transit and the ascending-colon residence time of the 0.2 mm resin was significantly shorter than that for the 5 mm tablets, though the magnitude of the effect was small.

In later experiments, stool water content was modulated and the influence of luminal water content on the absorption from the distal gut of either quinine (a transcellular probe) or [⁵¹Cr]-EDTA (a paracellular probe) was observed. Absorption of these probe markers from a timed-release delivery system was determined following treatment with lactulose 20 ml t.d.s. (increasing water content) or codeine 30 g q.d.s. (decreasing water content) and compared with control untreated values. Lactulose accelerated ascending-colon transit, increased stool water, caused greater dispersion of released material, and enhanced the absorption of the quinine compared to control. Conversely, codeine slowed down ascending colon, reduced stool water content, and also tended to diminish absorption. More distal release resulted in less absorption in the control arm, whereas lactulose enhanced drug absorption from the distal gut [71]. An interesting finding was that a proportion of the asymptomatic normal volunteers showed higher than expected urinary recoveries of [⁵¹Cr]-EDTA (5–10% of dose) suggesting an increased paracellular permeability.

Other workers have shown that the increased fluid load produced by an osmotic laxative results in redistribution of colonic contents. Since the distal colon is considered to be mainly a conduit without extensive storage function, Hammer and colleagues considered whether the capacity of the colon to retain fluid might be relevant in compensating for increased fluid loads and preventing diarrhea. Changes in distribution following cecal infusion of an iso-osmotic solution labeled with [^{99m}Tc]-DTPA containing polyethylene glycol (PEG; 500 ml) were compared with changes following infusion of an equal amount of readily absorbable electrolyte solution. After the osmotic load, fecal output was increased significantly ($p < 0.05$), but whole-colonic transit after PEG infusion was not different from transit after the

electrolyte solution ($p > 0.05$), indicating that the distal colon is able to manage nonabsorbable fluid volumes to a large extent [72].

21.6 Pathophysiological Effects on Transit

Active left-sided colitis is often resistant to topical therapy, and resolution may only be achieved by administration of systemic therapy. Twenty-two volunteers and ten patients were recruited for a clinical trial in which they received morning doses of a Eudragit-coated capsules containing [^{111}In]-labeled resin pellets [73]. At day 4 into the regime at steady state, the relative distribution of the marker was measured in the ascending, transverse, descending, and rectosigmoid colon. The results showed that colonic distribution among healthy subjects was asymmetric, with two-thirds of the administered dose in the proximal colon and one-third in the distal colon. In the patients, this difference was even more pronounced, with only one-tenth of the administered dose in the distal segment.

Rapid transit through this region suggests that the area is empty of colonic contents most of the time, and so the opportunity for topical treatment is consequently limited. If the exposure to a drug such as mesalazine is calculated on the basis of these data, the results show that treatment is probably inadequate. For example, the dose per day is approximately 3 g (800–1200 mg, t.d.s.), and therefore in active disease, the effective dose would be about 300 mg on the basis of this regimen. Doses of between 500 and 1000 mg are often given as an enema, but these doses are more effectively delivered and not sequestered within a viscous, partially dehydrated stool, as would be the case following oral administration. Modern “gold standard” treatment suggests that a combined oral and rectal dosing strategy is the most efficacious method of using this drug.

Although discrete effects of diseases are often noted by studying a single parameter such as gastric emptying, the effects of pathophysiological conditions, once established, are usually evident throughout the gut. Mollen and colleagues attempted to describe the motor activity of the upper gastrointestinal tract in patients with slow-transit constipation using perfusion manometry. Orocecal transit time was found to be similar between patients and controls, but esophageal motility was abnormal in 5 out of 18 patients and gastric emptying was abnormal in 8 out of 15 patients. These data support the case that disorders of upper gut motility occur frequently in patients with slow-transit constipation [74]. Gattuso studied 10 young patients with idiopathic megarectum using radiographic and scintigraphic methods. All patients had a dilated large bowel, with no radiographic evidence of upper gut dilation. Gastric emptying was normal in four patients and abnormally slow in six, which suggested that this bowel condition might be reflected in a disturbance of upper gut function. Both radioisotope scans and radio-opaque marker studies showed abnormal colonic transit, and regions of delay corresponded with the region of dilated bowel [75].

Studies in dogs have shown that postoperative ileus following surgery resolves an initial phase of weak irregular, nonpropagating contractions of the gastrointestinal tract, followed by transmission of the contractions from the upper gut to the lower gastrointestinal tract. Tsukamoto [76] found that recovery from postoperative ileus was aided by a change in the pattern of gastrointestinal motility in which contractions were transmitted from the stomach to the lower gastrointestinal tract, like an interdigestive migrating contraction. Bouchoucha characterized colonic transit time in 30 healthy subjects and in 43 patients with inflammatory bowel disease using X-ray opaque markers. The response to food was different in the two populations: in controls, the cecum and ascending colon emptied and filled the distal bowel, whereas in patients, only the splenic flexure and left transverse colon emptied. Movement through both the right and the left colon in patients was observed to be much slower than that in controls, both before and after a meal [77].

Patients with anxiety and depression often have bowel symptoms. Gorad and colleagues compared 21 psychiatric outpatients with generalized anxiety disorders and depression with an equal number of healthy controls. Whole-gut transit time (WGTT) was found to be shorter in patients with anxiety (mean 14 h; range 6–29 h) than in either those with depression (mean 49 h; range 35–71 h; $p < 0.001$) or controls (mean 42 h; range 10–68 h; $p < 0.001$). In patients with anxiety, orocecal transit time (measured using the lactulose hydrogen breath test) was shorter than in patients with depression and also shorter than in controls. The authors concluded that anxiety is associated with increased bowel frequency, while depressed patients tend to be constipated; taken together, these data strongly suggested that mood has an effect on intestinal motor function [78]. Bennett and colleagues [79] concluded that male hypochondriacs had normal intestinal transit, whereas elderly females with depressive illness were more likely to have both colonic and gastric stasis.

Among several disease conditions that affect gastric emptying, diabetes is probably the most extensively studied. Folwaczny and colleagues used scintigraphy to examine esophageal transit and gastric emptying and a metal-detector test to determine large bowel motility in patients with type I and type II diabetes. These authors concluded that both gastric emptying and large bowel transit were affected by both conditions [80].

The alteration of transit by disease, or a change produced by hydrodynamic factors such as diarrhea, will be highly significant for sophisticated zero-order release formulations such as osmotic pumps. For the pumps, inadequate retention may occur in some patients, perhaps leading to less optimal clinical outcome. Even in normal subjects, the range of intestinal transit time can be extreme; for example, the median gastrointestinal transit time for both oxprenolol and metoprolol OROS drug delivery systems has been reported as 27.4 h, with individual times ranging from 5.1 to 58.3 h [81].

Hammer [82] conducted an experiment in which volunteers received either autologous blood or egg white by duodenal intubation to simulate the condition of upper gastrointestinal bleeding. [^{99m}Tc]-DTPA was added to each infusion and arrival at, and clearance from, the colon was recorded. At 4 h after the start of blood infusion, a median of 30% of counts was observed in the transverse colon compared to 0% after

egg white administration; small intestinal transit was unaffected. Although it had been established that bleeding alters gastric motility, this demonstration for the first time that haem-containing proteins have a significant effect on proximal bowel motility.

21.7

Pathophysiological Effects on Permeability

Inflammation leads to changes in permeability of large and polar molecules, which forms the basis of diagnostic tests such as urinary recovery of [^{51}Cr]-EDTA after oral administration. Evidence for increased permeability to very large molecules and small particles in humans is limited, although in an experimental model of colitis in the rat, Lamprecht [83] demonstrated significant uptake of 100 nm-sized particles compared to controls.

21.8

pH

The pH changes of the gut are obvious triggers for the delivery of drug from enteric-coated preparations, in particular, tablets used for the delivery of topical agents in the treatment of bowel disease. Sasaki and coworkers measured pH profiles in the gut in patients with Crohn's disease by using a pH-sensitive radiotelemetry capsule as it traveled from the stomach to the cecum. Gastrointestinal pH profiles measured in four patients with left-sided Crohn's disease were similar to those in four gender- and age-matched control subjects. In contrast, colonic luminal pH profiles in both right and left colon in active or quiescent Crohn's disease showed more coarse fluctuations, with significantly lower values than were seen in controls [84].

The bulk luminal pH is heavily affected by the fermentation of carbohydrates to short-chain fatty acids; however, near the colonic mucosa, the pH rises and changes in the bulk pH have little effect on the epithelial microclimate. Bicarbonate/chloride exchange is partly responsible for raising the pH against the challenge posed by the high colonic p_{CO_2} and the acid production by fermentation. The mucus has been shown to contain a distinct carbonic anhydrase, produced by epithelial tissues that help to carefully regulate the thick unstirred layer of the colonic epithelium.

Many patients with Crohn's disease undergo an ileocecal resection, which might be expected to influence small intestinal pH and transit time. A "radiopill" technique (similar to that of Sasaki *et al.*) was used by Fallingborg and colleagues [85] to examine intraluminal pH and transit time in ileocecally resected Crohn's disease patients. These data were compared with those obtained from 13 healthy volunteers. The mean SITT was significantly shorter in patients than in controls (5.2 and 8.0 h, respectively). However, although the pH levels of the small intestine were identical in patients and controls, cecal pH was 0.9 pH units higher in resected Crohn's disease patients, and the period when the pH was elevated above 5.5 was significantly shorter in patients than in controls [86].

21.9

Conclusions

In summary, it is emphasized that disease conditions may result in changed physiological parameters that could strongly influence the effectiveness of orally administered medications. Changes in patterns of motility, pH, and amount of water available for dispersion and dissolution may be significant for patients compared to the “normal” population. On this basis, it seems appropriate to completely investigate the impact of a target disease – whether it is diabetes, inflammatory bowel disease, or irritable bowel syndrome – on the deposition of drug from the candidate delivery system. Neglect of these issues might lead to suboptimal therapy and a waste of healthcare resources.

References

- 1 Matolsky, A.G. and Parakkal, P.F. (1985) Membrane coating granules of keratinising epithelia. *The Journal of Cell Biology*, **24**, 297–307.
- 2 Salamat-Miller, N., Chittchang, M. and Johnson, T.P. (2005) The use of mucoadhesive polymers in buccal drug delivery. *Advanced Drug Delivery Reviews*, **57**, 1666–1691.
- 3 Smart, J.D. (2005) Buccal Drug Delivery. *Expert Opinion in Drug Delivery*, **2**, 507–517.
- 4 Bell, M.D.D., Murray, G.R., Mishra, P., Calvey, T.N., Weldon, B.D. and Williams, N.E. (1985) Buccal morphine: a new route for analgesia. *Lancet*, **1**, 71–73.
- 5 McElnay, J.C. and Hughes, C.M. (2002) Drug delivery: buccal route, in *Encyclopaedia of Pharmaceutical Technology* (ed. J. Swarbrick), Marcel Dekker, New York, pp. 800–810.
- 6 Gordon, D.B. (2006) Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. *Oncology Nursing Forum*, **33**, 257–264.
- 7 Squier, C.A. (1986) Penetration of nicotine and nitroso-nornicotine across porcine oral mucosa. *Journal of Applied Toxicology*, **6**, 123–128.
- 8 Adrian, C.A., Olin, H.B.D., Dalhoff, K. and Jacobsen, J. (2006) *In vivo* human buccal permeability of nicotine. *International Journal of Pharmaceutics*, **311**, 196–202.
- 9 Hoogstraate, J., Benes, J., Burgaud, S., Horriere, F. and Seyler, I. (2001) Oral trans-mucosal drug delivery, in *Drug Delivery and Targeting* (eds A.M. Hillery, A.W. Lloyd and J. Swarbrick), Taylor & Francis, London, pp. 186–206.
- 10 Portero, A., Remuñán-López, C. and Vila-Jato, J.L. (1998) Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine. *International Journal of Pharmaceutics*, **175**, 75–78.
- 11 Uzunoglu, B., Senel, S., Hincal, A.A., Ozalp, M. and Wilson, C.G. (2000) Formulation of a bioadhesive bilayered buccal tablet of natamycin for oral candidiasis. *Proceedings of the International Symposium on Control Related Bioactive Materials*, **27**, 8205.
- 12 Gordon, D.B. (2007) New opioid formulations and delivery systems. *Pain Management Nursing*, **8**, S6–S13.
- 13 Darwish, M., Kirby, M., Robertson, P., Jr, Tracewell, W. and Jiang, J.G. (2006) Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult

- volunteers. *Clinical Therapeutics*, **28**, 707–714.
- 14 Darwish, M., Kirby, M. and Jiang, J.G. (2007) Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. *Expert Opinion on Pharmacotherapy*, **8**, 2011–2016.
 - 15 Gallo, S.H., McClave, A., Makk, L.J. and Looney, S.W. (1996) Standardization of clinical criteria required for use of the 12.5 millimeter barium tablet in evaluating esophageal luminal patency. *Gastrointestinal Endoscopy*, **44**, 181–184.
 - 16 Osmanoglou, E., Van Der Voort, I.R., Fach, K., Kosch, O., Bach, D., Hartmann, V., Strenzke, A., Weitschies, W., Wiedenmann, B., Trahms, L. and Mönnikes, H. (2004) Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. *Neurogastroenterology and Motility*, **16**, 547–556.
 - 17 Ekeberg, O. and Feinberg, M.J. (1991) Altered swallowing function in elderly patients without dysphagia: radiologic findings in 56 cases. *American Journal of roentgenology*, **156**, 1181–1184.
 - 18 Richards, D.G., Mcpherson, J.J., Evans, K.T. and Rosen, M. (1986) Effects of volume of water taken with diazepam tablets on absorption. *British Journal of Anaesthesia*, **58**, 41–44.
 - 19 Perkins, A.C., Wilson, C.G., Frier, M., Blackshaw, P.E., Dansereau, R.J., Vincent, R., wenderoth, D., Hathaway, S., Li, Z. and Spiller, R.C. (2001) The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. *International Journal of Pharmaceutics*, **222**, 295–303.
 - 20 Hardy, J.G., Hooper, G., Ravelli, G., Steed, K.P. and Wilding, I.R. (1993) A comparison of the gastric retention of a sucralfate gel and a sucralfate suspension. *European Journal of Pharmaceutics and Biopharmaceutics*, **39**, 70–74.
 - 21 Dansereau, R.J., Dansereau, R.N. and Mcorrie, J.W. (1999) Scintigraphic study of oesophageal transit and retention, in *Nuclear Medicine in Pharmaceutical Research* (eds A.C. Perkins and M. Frier), Taylor & Francis, London, pp. 57–69.
 - 22 Potts, A.M., Wilson, C.G., Stevens, H.N.E., Dobrozsi, D.J., Washington, N., Frier, M. and Perkins, A.C. (2000) Oesophageal bandaging: a new opportunity for thermosetting polymers. *STP Pharma Sciences*, **10**, 293–301.
 - 23 Holt, S. (1981) Observations on the relation between alcohol absorption and the rate of gastric emptying. *Canadian Medical Association Journal*, **124**, 267–277.
 - 24 Wilson, C.G. (1999) Gastrointestinal transit and drug absorption, in *Oral drug Absorption* (eds J.D. Dressman and H. Lennernas), Marcel Dekker, New York, pp. 7–15.
 - 25 Washington, N., Steed, K.P. and Wilson, C.G. (1992) Evaluation of a sustained release formulation of the antacid almagate. *European Journal of Gastroenterology and Hepatology*, **4**, 495–500.
 - 26 O'reilly, S., Wilson, C.G. and Hardy, J.G. (1987) The influence of food on gastric emptying of multiparticulate dosage forms. *International Journal of Pharmaceutics*, **34**, 213–216.
 - 27 Faas, H., Steingoetter, A., Feinle, C., Rades, T., Lengsfeld, H., Boesiger, P., Fried, M. and Schwizer, W. (2002) Effects of meal consistency and ingested fluid volume on the intragastric distribution of a drug model in humans: a magnetic resonance imaging study. *Alimentary Pharmacology & Therapeutics*, **16**, 217–224.
 - 28 Weitschies, W., Wedemeyer, R.S., Kosch, O., Fach, K., Nagel, S., Söderlind, E., Trahms, L., Abrahamsson, B. and Mönnikes, H. (2005) Impact of the intragastric location of extended release

- tablets on food interactions. *Journal of Controlled Release*, **28**, 375–385.
- 29 Weitschies, W., Friedrich, C., Wedemeyer, R.S., Schmidtman, M., Kosch, O., Kinzig, M., Trahms, L., Sörgel, F., Siegmund, W., Horkovics-Kovats, S., Schwarz, F., Raneburger, J. and Mönnikes, H. (2008) Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. *European Journal of Pharmaceutics and Biopharmaceutics*, DOI: 10.1016/j.ejpb.2008.05.011.
 - 30 Washington, N., Moss, H.A., Washington, C. and Wilson, C.G. (1993) Non-invasive detection of gastro-oesophageal reflux using an ambulatory system. *Gut*, **34**, 1482–1486.
 - 31 Kelly, K., O'mahony, B., Lindsay, B., Jones, T., Grattan, T.J., Rostami-Hodjegan, A., Stevens, H.N.E. and Wilson, C.G. (2003) Comparison of the rates of disintegration, gastric emptying and drug absorption, following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. *Pharmaceutical Research*, **20**, 1668–1673.
 - 32 Edelbroek, M., Horowitz, M., Maddox, A. and Bellen, J. (1992) Gastric emptying and intragastric distribution of oil in the presence of a liquid or a solid meal. *Journal of Nuclear Medicine*, **33**, 1283–1290.
 - 33 Hellström, P.M., Grybäck, P. and Jacobsson, H. (2006) The physiology of gastric emptying. *Best Practices & Research. Clinical Anaesthesiology*, **20**, 397–407.
 - 34 Cuhe, G., Cuber, J.C. and Malbert, C.H. (2000) Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway. *American Journal of Physiology. Gastrointestinal and Liver Physiology*, **279**, G925–G930.
 - 35 Hunt, J.N. and Stubbs, D. (1975) The volume and energy content of meals as determinants of gastric emptying. *The Journal of Physiology*, **245**, 209–225.
 - 36 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies, December 2002.
 - 37 Ramkumar, D. and Schulze, K.S. (2005) The pylorus. *Neurogastroenterology and Motility*, **17** (Suppl. 1), 22–30.
 - 38 Marciani, L., Gowland, P.A., Fillery-Travis, A., Manoj, P., Wright, J., Smith, A., Young, P., Moore, R. and Spiller, R.C. (2001) Assessment of antral grinding of a model solid meal with echo-planar imaging. *American Journal of Physiology. Gastrointestinal and Liver Physiology*, **280**, G844–G849.
 - 39 Orr, W.C. and Chen, C.L. (2002) Aging and neural control of the GI tract. IV. Clinical and physiological aspects of gastrointestinal motility and aging. *American Journal of Physiology. Gastrointestinal and Liver Physiology*, **283**, G1226–G1231.
 - 40 Bortolotti, M., Frada, G.J.R., Barbagallo-Sangiogi, G. and Labo, G. (1984) Interdigestive gastroduodenal motor activity in the elderly (Abstract). *Gut*, **25**, A1320.
 - 41 Evans, M.A., Trigg, S.E.J., Cheung, M., Boe, G.A. and Creasey, H. (1981) Gastric emptying rates in the elderly: implication for drug therapy. *Journal of the American Geriatrics Society*, **29**, 201–205.
 - 42 Fich, A., Camilleri, M. and Phillips, S.F. (1989) Effect of age on human gastric and small bowel motility. *Journal of Clinical Gastroenterology*, **11**, 416–420.
 - 43 Madsen, J.L. (1992) Effects of gender, age, and body mass index on gastrointestinal transit times. *Digestive Diseases and Sciences*, **37**, 1548–1553.
 - 44 Brogna, A., Ferrara, R., Bucceri, A.M., Lanteri, E. and Catalano, F. (1999) Influence of aging on gastrointestinal transit time: an ultrasonographic and radiologic study. *Investigative Radiology*, **34**, 357–359.
 - 45 Baron, T.H., Ramirez, B. and Richter, J.E. (1993) Gastrointestinal motility disorders during pregnancy. *Annals of Internal Medicine*, **118**, 366–375.

- 46 Schiller, C., Fröhlich, C.P., Giessmann, T., Siegmund, W., Mönnikes, H., Hosten, N. and Weitschies, W. (2005) Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. *Alimentary Pharmacology & Therapeutics*, **22**, 971–979.
- 47 Spiller, R.C., Brown, M.L. and Phillips, S.F. (1987) Emptying of the terminal ileum in intact humans. Influence of meal residue and ileal motility. *Gastroenterology*, **92**, 724–729.
- 48 Dinning, P.G., Bampton, P.A., Kennedy, M.L., Kajimoto, T., Lubowski, D.Z., De Carle, D.J. and Cook, I.J. (1999) Basal pressure patterns and reflexive motor responses in the human ileocolonic junction. *The American Journal of Physiology*, **276**, G331–G340.
- 49 Charman, W.N., Porter, C.J.H., Mithani, S. and Dressman, J.B. (1997) Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. *Journal of Pharmaceutical Sciences*, **86**, 269–282.
- 50 Porter, C.J.H. and Charman, W.N. (2001) *In vitro* assessment of oral lipid based formulations. *Advanced Drug Delivery Reviews*, **50**, S127–S147.
- 51 Bryan, A.J., Kaur, R., Robinson, G., Thomas, N.W. and Wilson, C.G. (1980) Histological and physiological studies on the intestine of the rat exposed to solutions of Myrj 52 and PEG 2000. *International Journal of Pharmaceutics*, **7**, 145–156.
- 52 Baluom, M., Friedman, M. and Rubinstein, A. (1998) The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. *International Journal of Pharmaceutics*, **176**, 21–30.
- 53 Evans, A.M. (2000) Influence of dietary components on the gastrointestinal metabolism and transport of drugs. *Therapeutic Drug Monitoring*, **22**, 131–136.
- 54 Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A. and Langguth, P. (2001) Intestinal drug efflux: formulation and food effects. *Advanced Drug Delivery Reviews*, **50**, S13–S31.
- 55 Kiani, J. and Imam, S.Z. (2007) Medicinal importance of grapefruit juice and its interaction with various drugs. *Nutrition Journal*, **6**, 33.
- 56 Darbar, D., Dellorto, S., Morike, K., Wilkinson, G.R. and Roden, D.M. (1997) Dietary salt increases first-pass elimination of oral quinidine. *Clinical Pharmacology and Therapeutics*, **61**, 292–300.
- 57 Chang, T., Benet, L.Z. and Herbert, M.F. (1996) The effect of water-soluble vitamin E on cyclosporine kinetics in healthy volunteers. *Clinical Pharmacology and Therapeutics*, **59**, 297–303.
- 58 Frexinos, J., Bueno, L. and Fioramonti, J. (1985) Diurnal changes in myoelectrical spiking activity of the human colon. *Gastroenterology*, **88**, 1104–1110.
- 59 Narducci, F., Bassotti, G., Gaburri, M. and Morelli, A. (1987) Twenty four hour manometric recording of colonic motor activity in healthy man. *Gut*, **28**, 17–25.
- 60 Bassotti, G., Crowell, M.D. and Whitehead, W.E. (1993) Contractile activity of the human colon: lessons from 24 hour studies. *Gut*, **34**, 129–133.
- 61 Bassotti, G., Iantorno, G., Fiorella, S., Bustos-Fernandez, L. and Bilder, C.R. (1999) Colonic motility in man: features in normal subjects and in patients with chronic idiopathic constipation. *The American Journal of Gastroenterology*, **94**, 1760–1770.
- 62 Cook, B.J., Lim, E., Cook, D., Hughes, J., Chow, C.W., Stanton, M.P., Bidarkar, S.S., Southwell, B.R. and Hutson, J.M. (2005) Radionuclear transit to assess sites of delay in large bowel transit in children with chronic idiopathic constipation. *Journal of Pediatric Surgery*, **40**, 478–483.
- 63 Parker, G., Wilson, C.G. and Hardy, J.G. (1988) The effect of capsule size and density on transit through the proximal colon. *The Journal of Pharmacy and Pharmacology*, **40**, 376–377.

- 64 Watts, P.J., Barrow, L., Steed, K.P., Wilson, C.G., Spiller, R.C., Melia, C.D. and Davies, M.C. (1992) The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. *International Journal of Pharmaceutics*, **87**, 215–221.
- 65 Adkin, D.A., Davis, S.S., Sparrow, R.A. and Wilding, I.R. (1993) Colonic transit of different sized tablets in healthy-subjects. *Journal of Controlled Release*, **23**, 147–156.
- 66 Sathyan, G., Hwang, S. and Gupta, S.K. (2000) Effect of dosing time on the total intestinal transit time of non-disintegrating systems. *International Journal of Pharmaceutics*, **204**, 47–51.
- 67 Hebden, J.M., Gilchrist, P.J., Blackshaw, E., Frier, M.E., Perkins, A.C., Wilson, C.G. and Spiller, R.C. (1999) Night-time quiescence and morning activation in the human colon: effect on transit of dispersed versus large single unit formulations. *European Journal of Gastroenterology & Hepatology*, **11**, 1379–1385.
- 68 Huchzermeyer, H. and Schumann, C. (1997) Lactulose: a multifaceted substance. *Zeitschrift für Gastroenterologie*, **35**, 945–955.
- 69 Barrow, L., Steed, K.P., Spiller, R.C., Watts, P.J., Melia, C.D., Davies, M.C. and Wilson, C.G. (1992) Scintigraphic demonstration of accelerated proximal colon transit by lactulose and its modification by gelling agents. *Gastroenterology*, **103**, 1167–1173.
- 70 Barrow, L., Steed, K.P., Spiller, R.C., Maskell, N.A., Brown, J.K., Watts, P.J., Melia, C.D., Davies, M.C. and Wilson, C.G. (1993) Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental-model of diarrhea in man. *Digestive Diseases and Sciences*, **38**, 996–1003.
- 71 Hebden, J.M., Gilchrist, P.J., Perkins, A.C., Wilson, C.G. and Spiller, R.C. (1999) Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. *Pharmaceutical Research*, **16**, 1254–1259.
- 72 Hammer, J., Pruckmayer, M., Bergmann, H., Kletter, K. and Gangl, A. (1997) The distal colon provides reserve storage capacity during colonic fluid overload. *Gut*, **41**, 658–663.
- 73 Hebden, J.M., Perkins, A.C., Frier, M., Wilson, C.G. and Spiller, R.C. (2000) Limited exposure of left colon to daily dosed oral formulations in active distal ulcerative colitis: exploration of poor response to treatment? *Alimentary Pharmacology & Therapeutics*, **14**, 155–161.
- 74 Mollen, R.M.G.H., Hopman, W.P.M., Kuijpers, H.H.C. and Jansen, J.B.M.J. (1999) Abnormalities of upper gut motility in patients with slow-transit constipation. *European Journal of Gastroenterology & Hepatology*, **11**, 701–708.
- 75 Gattuso, J.M., Kamm, M.A., Morris, G. and Britton, K.E. (1996) Gastrointestinal transit in patients with idiopathic megarectum. *Diseases of the Colon & Rectum*, **39**, 1044–1050.
- 76 Tsukamoto, K., Mizutani, M., Yamano, M. and Suzuki, T. (1999) The relationship between gastrointestinal transit and motility in dogs with postoperative ileus. *Biological & Pharmaceutical Bulletin*, **22**, 1366–1371.
- 77 Bouchoucha, M.L., Dorval, E., Arhan, P., Devroede, G. and Arzac, M. (1999) Patterns of normal colorectal transit time in healthy subjects and in patients with an irritable bowel syndrome (IBS). *Gastroenterology*, **116**, G4192.
- 78 Gorard, D.A., Gomborone, J.E., Libby, G.W. and Farthing, M.J.G. (1996) Intestinal transit in anxiety and depression. *Gut*, **39**, 551–555.
- 79 Bennett, E.J., Evans, P., Scott, A.M., Badcock, C.A., Shuter, B., Hoschl, R., Tennant, C.C. and Kellow, J.E. (2000) Psychological and sex features of delayed gut transit in functional gastrointestinal disorders. *Gut*, **46**, 83–87.
- 80 Folwaczny, C., Hundegger, K., Volger, C., Sorodoc, J., Kuhn, M., Tatsch, K., Landgraf,

- R. and Karbach, U. (1995) Measurement of transit disorders in different gastrointestinal segments of patients with diabetes-mellitus in relation to duration and severity of the disease by use of the metal-detector test. *Zeitschrift für Gastroenterologie*, **33**, 517–526.
- 81** Grundy, J.S. and Foster, R.T. (1996) The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. *Clinical Pharmacokinetics*, **30**, 28–5160.
- 82** Hammer, J., Lang, K. and Kletter, K. (1998) Accelerated right colonic emptying after simulated upper gut hemorrhage. *The American Journal of Gastroenterology*, **93**, 628–631.
- 83** Lamprecht, A. Schafer, U. and Lehr, C.M. (2001) Size dependency of nanoparticle deposition in the inflamed colon in inflammatory bowel disease: *in vivo* results from the rat. *Journal of Controlled Release*, **72**, 235–237.
- 84** Sasaki, Y., Hada, R., Nakajima, H., Fukuda, S. and Munakata, A. (1997) Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. *The American Journal of Gastroenterology*, **92**, 114–118.
- 85** Fallingborg, J., Pedersen, F. and Jacobsen, B.A. (1998) Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. *Digestive Diseases and Sciences*, **43**, 702–705.
- 86** Kleinke, T., Wagner, S., John, H., Hewett-Emmett, D., Parkkila, S., Forssmann, W.-G. and Gros, G. (2005) A distinct carbonic anhydrase in the mucus of the colon of humans and other mammals. *The Journal of Experimental Biology*, **208**, 487–496.

22

Nanotechnology for Improved Drug Bioavailability

Marjo Yliperttula and Arto Urtti

Abbreviations

AUC	Area under the curve
BCS	Biopharmaceutical Classification System
CMC	Critical micelle concentration
DNA	Deoxyribonucleic acid
FDA	Food and Drug Administration
i.v.	Intravenous
PEG	Polyethylene glycol
SEAP	Secreted alkaline phosphatase
siRNA	Small interfering ribonucleic acid

Symbols

3D	Three-dimensional
CD44	Membrane receptor for the hyaluronan uptake into the cells

22.1

Introduction

Nanotechnology is one of the major fields of current pharmaceutical research. This field is strongly related to drug delivery and targeting, because nanosized drug delivery systems are able to modify the pharmacokinetics significantly. Based on the most common definition, nanotechnology is dealing with structures of below 1 μm . At very small sizes, material has peculiar physical chemical properties that are distinct from the macroscopic properties of the same matter. In pharmaceutical nanotechnology, these physical distinctions are not the main point. Rather, pharmaceutical nanotechnology aims to generate structural units below 1 μm and, most importantly, these particulates should have controlled functionalities that improve drug delivery.

Bioavailability is a parameter that defines the fraction of the dose that enters the “site of action.” In general, bioavailability refers to the *systemic bioavailability*. After per oral drug administration, the systemic bioavailability is always 0–100%, and the extent of bioavailability is determined by comparing the AUC values of the drug concentration in plasma versus time curves after oral and intravenous (i.v.) (100% bioavailability) drug administration [1]. There are some cases in which systemic bioavailability is improved with nanotechnology (e.g., nanocrystals). However, the main emphasis in the design of nanosystems is to improve *local bioavailability*. For example, nanotechnology is used to increase drug or gene delivery into the diseased target tissue, for example, vessel wall, tumor, or brain [2]. Another therapeutic goal is to improve the therapeutic index. Doxorubicin liposomes are a good example [3]. The drug as such is cardiotoxic as a solution, but liposomal doxorubicin avoids the toxicity by maintaining the free drug concentration in the blood stream at low level. Because the liposomes are preferentially distributed to the tumor tissue, the overall therapeutic index and efficacy of the treatment are improved.

Nanotechnology is a timely topic in pharmaceutical science and there are good reasons for that. *First*, in drug discovery, the solubility of new chemical entities shows historically a declining trend. In fact, poor water solubility has become one of the major problems that limit the systemic drug bioavailability. Nanosizing has been used to improve the rate of dissolution, and sometimes this method results in improved drug absorption after oral dosing [4]. *Second*, some target sites of drug treatment are difficult to reach. For example, narrow therapeutic index is a problem in anticancer drug treatment, as these drugs have serious adverse effects. If the doses could be reduced in association with improved drug delivery to the tumors, the extent of side effects would also be reduced. Other difficult targets include the brain and the posterior segment of the eye. *Third*, emerging biotechnological pharmacologically active compounds require nanotechnology-based drug delivery. This is because biotechnological drugs, such as peptides, proteins, oligonucleotides, and DNA, have large molecular weight, and they are not able to distribute in the body as small molecules do. The task is further complicated by the susceptibility of these drugs to enzymatic degradation by peptidases and nucleases. In many cases, the target sites are intracellular (e.g., siRNA, transcription factors, and DNA), and the delivery system should protect the drug from these enzymes and shuttle it to intracellular target sites [5]. In this case, the goal is to improve bioavailability in the cellular target organelles of the diseased tissue. In fact, the progress of these therapeutic approaches depends on the possibility to efficiently deliver these compounds to the target sites. In the case of gene medicines, it is straightforward to find the drug (i.e., DNA or siRNA sequence) after biological basic research on the mechanisms of the disease. However, drug delivery becomes the limiting factor.

Nanotechnologists are constructing new smart materials at an increasing pace. It is, however, important to realize that only a small part of the invented materials is applicable in medicine due to the limiting issues of toxicology and materials safety. Nanotoxicology has gained a lot of publicity, but the most serious safety issues are related to the technical use of nanoparticles and to the unintentional exposure to these materials [6]. Nanopharmaceuticals must be tested in preclinical toxicological tests and in clinical studies. Therefore, these products are not expected to have more

safety problems than regular pharmaceutical products after their acceptance for the clinical use.

In this chapter, we describe different nanotechnological systems for drug delivery and their potential applications for improved systemic and local bioavailability. The chapter is an overview that hopefully guides the interested reader to the more detailed texts on this issue.

22.2

Nanotechnological Systems in Drug Delivery

Nanotechnological systems have a particle size in the nanometer scale (1–1000 nm). In general, these systems can be divided into top-to-down and bottom-to-top systems. The first category includes nanosystems that are made by processing larger particles to smaller units. For example, drug nanocrystals are produced by milling larger particles to nanosize [4]. Bottom-to-top systems are constructed from molecules that adhere to each other thereby forming associated structures in the nanoscale. These systems are based on the principles of self-assembly and they have particular advantage of spontaneous formation and functional versatility.

22.2.1

Classification of the Technologies

The following paragraphs briefly describe the main categories of nanostructures that are relevant in drug delivery. The main points are compiled in Table 22.1.

22.2.1.1 Nanocrystals

Nanocrystals are small drug particles, usually about 100 nm in diameter, which are produced by milling drug particles in the presence of surfactant. Eventually, the

Table 22.1 Classification of nanotechnological drug delivery systems.

Class	Approximate size range (nm)	Applications	Clinical status
Nanocrystals	100–200	Dissolution enhancement	Accepted
Dendrimers	5–10	Drug targeting	Experimental
Nanoparticulates			
Liposomal	50–500	Intravenous drug delivery Localized drug delivery	Accepted Experimental
Micelles	10	Drug delivery, solubilization (i.v.)	Accepted
Albumin	130	Intravenous drug delivery	Accepted
Polymeric	100–200	Drug delivery	Experimental
Peptide vesicles	10–100	Drug delivery	Experimental
Targeted nanoparticles	10–200	Site-specific drug delivery	Experimental
Nucleic acid complexes	50–200	DNA and siRNA delivery	Experimental

surfactant will cover the surface of the drug nanocrystals [4]. The main use of such particles is in the field of dissolution enhancement. Poorly soluble drugs (BCS class III and IV) show typically very slow dissolution, and, for that reason, they do not dissolve adequately during the passage of the tablet in the small intestine (typical transit time is 3 h). According to the law of Noyes and Whitney that is already more than 100 years old, increased surface area of the powder increases the rate of dissolution. From the bioavailability point of view, the increased dissolution rate is meaningless for most of the class I and class II compounds because their entire dose would dissolve anyway rapidly. In the case of class III and class IV compounds, the rate of drug dissolution can make a great difference. This was shown early in the case of digoxin when the importance of digoxin particle size on bioavailability was demonstrated [7]. There is indeed clear rationale for the use of nanocrystals in oral drug delivery.

22.2.1.2 Self-Assembling Nanoparticulates

Self-assembled nanoparticulates comprise various kinds of polymeric, peptide-based, and lipoidal systems. The rationale for their pharmaceutical use is to incorporate the drug into the system and thereby modify its solubility or delivery.

Self-assembled delivery systems form spontaneously in water solution when the structural component is added to water. Amphiphilic compounds form such structures and the features of the resulting nanostructures depend on the molecular properties of the amphiphile. Typically, these systems have a critical association concentration (e.g., critical micelle concentration (CMC)). Below this concentration, the compound exists as individual molecules (monomers) and orient toward the surface of water. Above the critical concentration self-associated structures are formed. The relative sizes of the polar head group and nonpolar chains determine the critical association concentration and morphology of the resulting structures. Micelles are formed by surfactants that have relatively large head groups compared to their nonpolar ends. Lamellar phases (i.e., liposomes) are formed when the both ends are of similar size. Tubular hexagonal phases result from the self-association of the molecules with small polar group relative to the wide hydrophobic end of the molecule. Lipid-like amphiphilic molecules can adopt various 3D structural orientations, which have been summarized earlier.

In addition to lipid-like molecules, polymers can also form self-assembling particulates [8]. As expected, the amphiphilic polymers do form polymeric micelles with polar part orienting towards the surface of the particle and the hydrophobic part orienting towards the core of the particle. Also, in this case, different complicated self-assembled structures can be tailored by using block copolymers with regular blocks of monomer units; but, only the simpler ones have been investigated so far in the context of drug delivery.

Biological molecules do show regularity at the level that is not obtained with synthetic polymers. Protein folding is a perfect example, but it is not yet well understood. Therefore, protein-based 3D drug delivery systems are difficult to design. However, small peptides with amphiphilic structure (e.g., V₆K, where six valines form hydrophobic part and lysine is the hydrophilic end group) can assemble

to form vesicles or tubes [9]. Peptides with regular repeating units may also self-assemble to fiber structures [10]. DNA, RNA, and oligonucleotides are versatile materials due to their ability to exactly recognize the complimentary sequences. Nanotechnologists have tailored even smiley-shaped DNA nanostructures. The self-assembling peptides and DNA-based nanostructures have only sparsely been explored in the field of drug delivery.

The size of the self-assembled amphiphilic structures varies from about 10 nm to a micron scale. Micelles are smaller than the vesicles, because they do not have internal aqueous core, and the wall is monolayer, not bilayer like in the liposomes.

22.2.1.3 Processed Nanoparticulates

Polymeric nanoparticles and nanocapsules are usually based on processing [11]. The processing may involve dispersion of the polymer solution in the dispersed organic phase in the continuous water phase and subsequent precipitation of the polymer by changes in the solvent composition. Nanoparticulates can be produced also by spraying techniques, including electrospraying [12]. The most commonly used materials include polylactide and polyglycolide and their copolymers. They are FDA-approved biodegradable materials with safe degradation products.

22.2.1.4 Single-Molecule-Based Nanocarriers

In the aforementioned cases, each particle contains typically at least thousands of molecules that are bound to each other by secondary chemical forces. The progress of chemistry since 1990s has provided a new class of materials, the dendrimers [13]. They are dendritic structures that are synthesized in generations around a core molecule that serves as a starting point. Large dendrimers may have even 10 generations, which means that it has 10 layers of dendritic structures in onion-like conformation. The simple dendrimers have spherical shape and they are much more monodisperse than most other synthetic polymers. Dendrimers are interesting materials for drug delivery purposes. They have been used for DNA and oligonucleotide delivery [14], but the dendritic shape as such does not provide improved properties compared to similar chemistry (poly-L-lysine) but linear or branched shape [15].

22.2.2

Pharmaceutical Properties of Nanotechnological Formulations

22.2.2.1 Drug-Loading Capacity

Drug-loading capacity of the system defines the dose of drug per individual particle. In principle, solid drug nanoparticle has the maximal loading capacity because it is nearly 100% drug. Drug nanocrystals have been mostly used for dissolution enhancement. In this context, the surface area per milligram of drug is the key parameter and this is defined by the particle size. For intracellular drug delivery and targeting, solid nanoparticles of pure drug have rarely been used. Abraxane is a paclitaxel product that is administered intravenously [16]. It contains drug crystals associated with albumin, but this is not a delivery system for intracellular drug

delivery, rather an approach to improve the drug dissolution after injection. The size of individual albumin molecules is 4–6 nm, whereas the paclitaxel-containing albumin nanoparticles are about 130 nm in diameter.

Vesicular systems can encapsulate both hydrophilic and hydrophobic drugs. They are localized either in the membrane (lipophilic) or in the aqueous core (hydrophilic) of the delivery system. In general, the micellar systems (surfactant or polymer based) are useful for the loading of hydrophobic drugs. Importantly, the size of the vesicular systems, such as liposomes, is in the range of 100–500 nm, and micellar systems are in the range of 5–10 nm. In terms of volume and drug-loading capacity per particle, this is a huge difference because the particle volume is proportional to the (radius)³ of the particle. Tenfold difference in the radius means thousandfold difference in the volume. Therefore, drug dose that is delivered per particle upon endocytosis is much bigger with larger particles than with the small micellar structures. However, the smaller micellar particles more easily gain access to the tissues because they can more easily extravasate from the blood circulation to the tissues.

Drug loading into nanoparticles can also depend on charge. For example, efficient loading of negatively charged nucleic acid-based drugs into the positively charged micelles, liposomes, or dissolved polymers is achieved by electrostatic binding [17]. This results in the formation of a new nanoparticle complex and disruption of the original liposomal or micellar structure.

22.2.2.2 Processing

The processing of the nanoparticulate structures is out of the scope of this chapter. It is important, however, to notice that in some cases the nanoparticulates may form spontaneously and drug is partitioned to the nanoparticulate structure by simple mixing. However, loading of hydrophilic drugs into liposomes requires reverse-phase evaporation or other processing methods, and likewise drug encapsulation into the polymeric nanoparticles often requires special processing. These factors depend on the drug and carrier properties and they are designed case by case.

22.2.2.3 Biological Stability

Biological stability of nanoparticles is an important determinant of their applications. The stability depends on the nanoparticle class.

In the case of self-assembling nanoparticulates, the critical association concentration affects their behavior. If the critical concentration of the amphiphile is high, the concentration may decrease after intravenous injection below the critical value thereby resulting in the dissociation of the particles [18]. This is the reason why surfactant-based micelles, with CMC in the millimolar range, are not useful as intravenous drug targeting vehicles as they do not retain their integrity long enough to enable improved target site bioavailability. Such micelles are, however, useful in solubilization of the drug to avoid the drug-induced irritation. If micellar drug solution is applied to extravascular site with limited dilution upon administration, the self-associated micelles may remain intact and enable localized drug delivery (e.g., in the skin).

Phospholipids have low CMC values in the nanomolar range. Therefore, this class of nanoparticulates is more suitable for intravenous administration, because the

phospholipid concentration remains above CMC even after i.v. injection. Thus, liposomal products are successful in the intravenous delivery of anticancer agents and the liposomes do not disintegrate in the blood circulation. Owing to their integrity, normal phospholipid liposomes are too stable for transdermal drug delivery. After their application on the skin, the liposomes stay on the skin surface and do not facilitate drug delivery across the skin. Only special classes of lipids, fusogenic hexagonal phase forming lipids such as DOPE or lysophospholipids, are able to fuse to the skin lipids and facilitate transdermal drug delivery by permeabilizing the skin barrier [19].

Polymeric micelles have critical association concentrations that can be modified by the polymer structures. The critical concentrations are lower than those in the case of surfactant-based micelles enabling the stability of the polymeric micelles in the circulation [18]. Polymeric micelles have been used successfully for drug targeting intravenously.

Typically, the processed polymeric nanoparticles are stable in the blood stream and elsewhere in the body [20]. Their degradation and drug release are determined by the chemical degradation rate of the polymer such as poly(lactide) and poly(glycolide). Such nanoparticles can be used for site-specific intracellular drug delivery if they have targeting moieties on the surface.

22.3

Delivery via Nanotechnologies

22.3.1

Delivery Aspects at Cellular Level

In principle, the nanotechnological systems could facilitate the overcoming of the biological barriers at tissue and cell levels.

Nanoparticulates may get across the *tissue barriers* depending on the type of the delivery system and tissue boundary (Figure 22.1). The size of the nanoparticulates is relatively large compared to the size of small molecular weight drugs. In tight epithelial and endothelial tissue linings, the size of the paracellular penetration pathway is about 2–3 nm [21]. This is clearly smaller than the size of the nanocarriers (10–1000 nm). Only some metallic nanoparticles, such as gold nanoparticles, can be in the size range that should allow paracellular penetration across tight epithelia. Current nanosystems do not fuse with the cell membranes either, and therefore, the only possible mechanism for crossing the tight epithelial and endothelial barriers is by transcytosis (Figure 22.1a) [22]. This process requires specific docking on the cell surface receptor, subsequent transcytosis, and release from the basolateral side of the membrane. Without specific cell biological mechanisms, the nanoparticulate systems are not useful in drug delivery across tight junction containing membranes, such as small intestinal wall, cornea, blood–brain barrier, and nasal epithelium.

There are several tissue boundaries in the body with more leaky character. For example, the vascular endothelium in the liver and spleen allows passage of even




Figure 22.1 Nanoparticle-mediated drug delivery across the tight (a) and leaky (b) tissue barriers. In the case of nanocrystals and drug solubilization systems, the dissolution rate is increased and free drug permeates across the tissue barrier with the appropriate mechanism. The nanoparticle-bound drug behaves differently. The nanoparticles are too large for the direct transcellular permeation across the cells' walls (I), for the paracellular diffusion through the tight tissue boundaries (a-II), and for the active transport by membrane transporters

(III). The tight tissue boundaries include the intestinal wall, skin, cornea, conjunctiva, blood–brain barrier, placental barrier, and blood–retina barrier. In leaky tissue boundaries (e.g. fenestrated endothelia, sinusoidal vessels, and tissue boundaries disrupted by the disease states such as inflammation), the nanoparticles may pass the barrier by paracellular permeation. In specific cases, receptor-mediated transcytosis may be possible (IV), but in this case specific recognition and transport mechanisms must be utilized.

micrometer-scale particles, and tumor vasculature can be extravasated by nanoparticles of 200 nm and smaller (Figure 22.1b). In addition, many localized tissues such as vitreous in the eye or coronary vessel walls allow nanoparticle diffusion after local administration.

In the case of *intracellular targeting* of the nanoparticles, it is important to consider the intracellular target organelle, nanoparticle type, and characteristics of the cell (Figure 22.2). Nanoparticles are simply too large to diffuse across cell membranes. They may, however, enter the cells via endocytic mechanisms [23]. These mechanisms involve binding of the nanoparticles to the cell surface and subsequent invagination of the cell membrane and formation of the endosomal vesicle (Figures 22.1 and 22.2). The size of the nanoparticle is important in this process. Only a few specialized professional phagocytic cells, such as macrophages and retinal pigment epithelium, are able to engulf large micrometer-sized particles [24]. Most cell types can endocytose only nanoparticles that are less than 200 nm in diameter. Endocytosis can be a receptor-mediated specific process, a nonspecific fluid-phase process, or an adherence-based process.

The endosomes can be further divided into clathrin-coated pits and caveolae [25]. The former is acidified and they deliver their contents to the lysosomes. Depending on the case, lysosomal delivery can be beneficial or vice versa. Nanosystems can be designed to release the drug resulting from the action of specific lysosomal enzymatic




Figure 22.2 Fates of nanoparticles after i.v. injection and local administration to the target tissue. After i.v. injection, the particles should avoid aggregation and embolization to avoid entrapment into the lung capillaries. Kupffer cells of the liver phagocytose major part of the nanoparticle dose (illustrated on the right), but this may be slowed down by nanoparticle surface modifications. In the target tissue (on the left), the nanosystem should enter the vascular endothelial cells, if they are the target cells, like in the case of neovascularization. Otherwise, they should escape from the vasculature, dock to the

target cell surface, and internalize into the target cells by endocytosis. Depending on the case, the intracellular target may be cytosolic, lysosomal, nuclear, or elsewhere. With the exception of the lysosomal targets, the nanoparticles should escape from the endosomes and enter the cytoplasm (e.g., siRNA) or nucleus (e.g., DNA). The nanoparticles may be injected or given directly to the tissue of interest. Then, the barriers of Kupffer cells and vascular walls are avoided. The issues of cellular uptake and intracellular kinetics are relevant also in this case. This figure is taken from Ref. [43].

cleavage. In this case, the drug as such should be resistant to the acidic lysosomal pH and the catalytic activity in this organelle. In many cases, the lysosomal delivery should be avoided, and the drug ought to escape from the endosomes to the cytoplasm before entering the lysosomes. The escape can be facilitated with special

design of the nanoparticulates. For example, the acidification in the endosomes (from pH 7.4 to 5.5) and reducing environment can be utilized as triggering mechanisms that allow nanoparticulate activation and endosomal escape [26]. Membrane-active peptides, pH-sensitive lipids, and reducing polymer structures with disulfide bridges have been utilized as nanoparticulate components for this purpose.

Cytoplasm is an important target for siRNA and antisense oligonucleotides whereas transcription factors and plasmid DNA should be delivered into the nucleus (Figure 22.2). Cytoplasm is a highly viscous medium where passive diffusion of nanoparticles, and macromolecules are very slow [27]. It is very appealing to search for the means by which the nanoparticulate transport in the cytoplasm and delivery into the nucleus can be maximized [28]. Specific nuclear localizing peptides have been attached to the nanoparticulates for the nuclear delivery but their efficacy is still not adequate [29].

22.3.2

Nanosystems for Improved Oral Drug Bioavailability

The steps in oral drug absorption have been described in detail elsewhere in this book. The preceding discussion about the cellular interactions of the nanoparticulates suggests that the nanoparticles are not physically optimal for drug delivery across the relatively tight intestinal wall (Figure 22.1). Rather, other mechanisms are more viable. *First*, the nanoparticulates can be used to improve drug dissolution especially in the case of BCS class III and class IV compounds. This can be accomplished by making pure drug nanocrystals, as discussed above. Another alternative is to use self-assembling structures, such as self-emulsifying systems, to solubilize the poorly soluble drugs [30]. These techniques have shown some improvement in systemic bioavailability after oral drug administration. *Second*, the retention time of the particles in the intestine can be prolonged by adhering the particles to the gut wall. This approach involves the use of lectin moieties at the particle surface. Lectin binds to carbohydrates on the gut wall and generates higher localized drug concentration next to the intestinal wall thereby increasing drug absorption [31]. *Third*, the transcytosis mechanism can be used [22]. As far as the third approach is concerned, only vitamin B-12 utilizes transcytosis in its absorption [32]; otherwise, this approach has not been successful. It is difficult to obtain high enough permeation through the intestinal wall with this mechanism.

It is important to realize that in the first and second option, the local concentration of the free drug is increased by the nanosystems. The drug may be absorbed by passive diffusion or active transport, but it is not specifically carried by the nanoparticulates.

22.3.3

Nanosystems for Improved Local Drug Bioavailability

Improved local tissue-specific bioavailability can be reached either by systemic administration intravenously or by localized direct injection in the vicinity of the target tissue (Figure 22.2).

The local administration of the nanoparticles can be used either to increase the retention at the site of administration or to control the drug release. Intravitreal drug administration into the eye is an interesting example. If a small molecular weight drug is administered in the form of water solution to the vitreous, the concentration decreases rapidly, because the drug diffuses to the systemic circulation across the blood–retina barrier or via the anterior chamber [33]. Therefore, the drug concentration profile in the vitreous shows rapid decline after initial high concentration peak. When the drug is administered in the liposomes, prolonged concentration profile is obtained due to the hindered permeation of the liposomes across the barriers. Thus, nanoparticulates modulate the concentration profile of the free drug in the vitreous by removing the high-peak concentration and by prolonging the retention in the vitreous. Similar principles are applicable to many other sites of localized injections: nanoparticulates increase drug retention at the site of injection and modify the concentration profile toward controlled release profile (e.g., at the surgical sites).

If cell-specific targeting is sought, the nanoparticle should bear appropriate ligands on its surface to recognize the cell of interest. This was exemplified by recent study with nanoparticulates that recognize CD44 receptors responsible for internalization of hyaluronic acid-coated DNA complexes [34]. Lipid–DNA nanoparticulates were also able to transfect corneal epithelial cell surface that released the encoded protein to the basolateral side of the epithelium [35]. As such, the protein would not diffuse through the tight junctions on the corneal epithelial surface (Figure 22.3). This




Figure 22.3 Epithelial cells can be transfected to serve as secreting platform of the therapeutic protein. Protein as such does not permeate across the tissue boundary. The nanoparticulates that encode the protein also cannot permeate the epithelial barrier, but they can internalize to the outer most all layer of the epithelium. These cells are transfected and subsequently secrete the

therapeutic protein to the basolateral target compartment. This principle of circumventing the apical tight junctions was demonstrated recently in the eye [35]. DNA nanoparticulates were administered to the tear side of the cornea and the transgene product, SEAP, was secreted to the anterior chamber of the eye.

method circumvents the tight epithelial barrier by transfecting the surface cells to secrete the therapeutic protein to the other side of the barrier.

The systemic i.v. administration can be used for targeted localized drug delivery with nanosystems (Figure 22.2). This is particularly appealing in the case of cancer medications, because these drugs cause serious adverse effects at therapeutic doses [36]. In addition, the metastases are difficult to treat with local injections. Therefore, most nanoparticulate studies dealing with systemic administration are directed to the cancer treatments. This approach is not an easy one, because a major fraction of the nanoparticulate dose is captured by Kupffer cells in the liver (Figure 22.2). The half-life of the particles in the circulation is increased by the “stealth” coating of the particles. Polyethylene glycol (PEG) moieties on the nanoparticulate (polymeric micelle, liposome, polymeric nanoparticle, and DNA complexes) surface prevent the adherence of plasma proteins on the surface. Therefore, the Kupffer cells do not recognize these particles and long retention times in plasma (1–2 days) are achieved. Eventually, a large fraction of these particles ends up in the liver as well, albeit at a slower rate. The particles must extravasate from the blood circulation, and PEG-coated nanosystems have a higher probability of extravasation in the tumors due to their leaky vasculature. Thereafter, the cell-level issues (see above) determine the fate and therapeutic efficacy of the nanoparticulate systems (Figure 22.2).

Systemic administration of drugs in the form of nanoparticulates intravenously has been widely studied. Currently, there are some liposomal anticancer and antifungal medications in clinical use. These products show relative increase in drug bioavailability in the target sites. They are not, however, active targeting systems with recognition ligands on the surface.

22.4

Key Issues and Future Prospects

The delivery of drugs to difficult-to-reach targets, such as brain and tumors, remains a major challenge. Biotechnological drugs, such as gene medicines and some proteins, need improved nanotechnological formulations for their intracellular delivery. Design of such delivery systems requires interplay between the delivery system and the biological machinery to reach the therapeutic goals. Viruses have evolved to use the cells for their own purposes and in doing so they deliver their genetic cargo into the target cells in elegant ways. Successful functional mimicking of biological self-assembling nanostructures is essential to the progress in this field.

Another important future issue in the field of drug delivery nanotechnology is the use of smart responsive materials and small devices based on such materials. The materials may take into account the human physiology by releasing the drug at needed rate at the right time. These systems are also applicable in the design, fabrication, and use of advanced nanobiosystems for cellular integration and tissue engineering. The opportunities exist for the use of functional biomaterials and therapeutic drug targeting and delivery systems that combine both biological and

engineering aspects of drug delivery [37], like in the case of the off-water fabrication and surface modification device consisting of asymmetric 3D SU-8 microparticles for drug delivery and tissue engineering [38].

Nanoparticulate systems can be designed to bear multiple components and functions, including activation at the target site or by external signal (e.g., light or magnetic field) [39, 40]. Such future trends would also involve the use of new types of nanomaterials, such as carbon nanotubes [41] and functionalized metallic nanoparticles [42]. Taking the safety issues into account is an imperative, as many nanomaterials for the technical purposes do not meet the criteria that are required for pharmaceutical materials. Anyway, it is likely that the current research investments in the fields of nanomedicine and pharmaceutical nanotechnology will lead to improved drug therapies by improving the drug bioavailability at the target site.

References

- 1 Rowland, M. and Tozer, T. (1995) *In Clinical Pharmacokinetics, Concepts and Applications*, Lippincott, USA.
- 2 Turunen, M.P., Hiltunen, M.O., Ruponen, M., Virkamäki, L., Szoka, F.C., Urtti, A. and Ylä-Herttuala, S. (1999) Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer–plasmid complexes. *Gene Therapy*, **6**, 6–11.
- 3 Allen, T.M., Cheng, W.W.K., Hare, J.I. and Laginha, K.M. (2006) Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. *Anti-Cancer Agents in Medicinal Chemistry*, **6**, 513–523.
- 4 Merisko-Liversidge, E., Liversidge, G.C. and Cooper, E.R. (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. *European Journal of Pharmaceutical Sciences*, **18**, 113–120.
- 5 Liu, F. and Huang, L. (2002) Development of non-viral vectors for systemic gene delivery. *Journal of Controlled Release*, **78**, 259–266.
- 6 Stern, S.T. and McNeil, S.E. (2008) Nanotechnology safety concerns revisited. *Toxicological Sciences*, **101**, 4–21.
- 7 Shaw, T.R.D. and Carless, J.E. (1974) The effect of particle size on the absorption of digoxin. *European Journal of Clinical Pharmacology*, **7**, 269–273.
- 8 Kataoka, K., Harada, A. and Nagasaki, Y. (2001) Block copolymer micelles for drug delivery: design, characterization and biological significance. *Advanced Drug Delivery Reviews*, **47**, 113–131.
- 9 van Hell, A.J., Costa, C.I.C.A., Flesch, F.M., Sutter, M., Jiskoot, W., Crommelin, D.J.A., Hennink, W.E. and Mastrobattista, E. (2007) Self-assembly of recombinant amphiphilic oligopeptides into vesicles. *Biomacromolecules*, **8**, 2753–2761.
- 10 Hosseinkhani, H., Hosseinkhani, M. and Kobayashi, H. (2006) Design of tissue-engineered nanoscaffold through self-assembly of peptide amphiphile. *Journal of Bioactive and Compatible Polymers*, **21**, 277–296.
- 11 Galindo-Rodríguez, S.A., Puel, F., Briançon, S., Allémann, E., Doelker, E. and Fessi, H. (2005) Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. *European Journal of Pharmaceutical Sciences*, **25**, 357–367.
- 12 Jaworek, A. (2007) Micro- and nanoparticle production by electrospraying. *Powder Technology*, **176**, 18–35.
- 13 Liu, M. and Fréchet, J.M.J. (1999) Designing dendrimers for drug delivery.

- Pharmaceutical Science & Technology Today*, **2**, 393–401.
- 14** Tang, M.X. and Szoka, F.C. (1997) The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. *Gene Therapy*, **4**, 823–832.
- 15** Männistö, M., Vanderkerken, S., Toncheva, V., Ruponen, M., Elomaa, M., Schacht, E.H. and Urtti, A. (2002) Structure–activity relations of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. *Journal of Controlled Release*, **83**, 169–182.
- 16** Gradishar, W.J. (2006) Albumin-bound paclitaxel: a next-generation taxane. *Expert Opinion on Pharmacotherapy*, **7**, 1041–1053.
- 17** Hyvönen, Z., Plotniece, A., Reine, I., Checavichus, B., Duburs, G. and Urtti, A. (2000) Novel cationic amphiphilic 1,4-dihydropyridine derivatives for DNA delivery. *Biochimica et Biophysica Acta*, **1509**, 451–466.
- 18** Torchilin, V.P. (2001) Structure and design of polymeric surfactant-based drug delivery systems. *Journal of Controlled Release*, **73**, 137–172.
- 19** Kirjavainen, M., Urtti, A., Jääskeläinen, I., Suhonen, T.M., Paronen, P., Valjakka, R., Kiesvaara, J. and Mönkkönen, J. (1996) Interaction of liposomes with human skin *in vitro*: the influence of lipid structure. *Biochimica et Biophysica Acta*, **1304**, 179–189.
- 20** Stolnik, S., Illum, L. and Davis, S.S. (1995) Long circulating microparticulate drug carriers. *Advanced Drug Delivery Reviews*, **16**, 195–214.
- 21** Hämäläinen, K.M., Kontturi, K., Murtomäki, L., Auriola, S. and Urtti, A. (1997) Estimation of pore size and porosity of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach. *Journal of Controlled Release*, **49**, 97–104.
- 22** Kreuter, J. (2001) Nanoparticulate systems for brain delivery of drugs. *Advanced Drug Delivery Reviews*, **47**, 65–81.
- 23** Panyam, J. and Labhasetwar, V. (2003) Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. *Pharmaceutical Research*, **20**, 212–220.
- 24** Tuovinen, L., Ruhanen, E., Kinnarinen, T., Rönkkö, S., Pelkonen, J., Urtti, A., Peltonen, S. and Järvinen, K. (2004) Starch acetate microparticles for drug delivery into retinal pigment epithelium. *Journal of Controlled Release*, **98**, 407–413.
- 25** Lai, S.K., Hida, K., Man, S.T., Chen, C., Machamer, C., Schroer, T.A. and Hanes, J. (2007) Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. *Biomaterials*, **28**, 2876–2884.
- 26** Jääskeläinen, I., Lappalainen, K., Honkakoski, P. and Urtti, A. (2004) Requirements for delivery of active antisense oligonucleotides into cells via lipid carriers. *Methods in Enzymology*, **387**, 210–230.
- 27** Lukacs, G.L., Haggie, P., Seksek, O., Lechardeur, D., Freedman, N. and Verkman, A.S. (2000) Size-dependent DNA mobility in cytoplasm and nucleus. *Journal of Biological Chemistry*, **275**, 1625–1629.
- 28** Eguchi, A., Furusawa, H., Yamamoto, A., Akuta, T., Hasegawa, M., Okahata, Y. and Nakanishi, M. (2005) Optimization of nuclear localization signal for nuclear transport of DNA-encapsulating particle. *Journal of Controlled Release*, **104**, 507–519.
- 29** van der Aa, M.A.E.M., Koning, G.A., d'Oliveira, C., Oosting, R.S., Wilschut, K.J., Hennink, W.E. and Crommelin, D.J.A. (2005) An NLS peptide covalently linked to linear DNA does not enhance transfection efficiency of cationic polymer based gene delivery systems. *Journal of Gene Medicine*, **7**, 208–217.

- 30 Pouton, C.W. (2006) Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *European Journal of Pharmaceutical Sciences*, **29**, 278–287.
- 31 Gabor, F., Bogner, E., Weissenboeck, A. and Wirth, M. (2004) The lectin–cell interaction and its implications to intestinal lectin-mediated drug delivery. *Advanced Drug Delivery Reviews*, **56**, 459–480.
- 32 Bose, S., Kalra, S., Yammani, R.R., Ahuja, R. and Seetharam, B. (2007) Plasma membrane delivery, endocytosis and turnover of transcobalamin receptor in polarized human intestinal epithelial cells. *Journal of Physiology*, **581**, 457–466.
- 33 Barza, M., Stuart, M. and Szoka, F. (1987) Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. *Investigative Ophthalmology & Visual Science*, **28**, 893–900.
- 34 Hornof, M., Fuente, M., Hallikainen, M., Tammi, R. and Urtili, A. (2008) Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. *Journal of Gene Medicine*, **10**, 70–80.
- 35 Toropainen, E., Hornof, M., Kaarniranta, K. and Urtili, A. (2007) Corneal epithelium as a platform for secretion of transgene products after transfection with liposomal gene eyedrops. *The Journal of Gene Medicine*, **9**, 208–216.
- 36 Northfelt, D.W., Martin, F.J., Working, P., Volberding, P.A., Russell, J., Newman, M., Amantea, M.A. and Kaplan, L.D. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. *Journal of Clinical Pharmacology*, **36**, 55–63.
- 37 Saltzman, M. and Desai, T. (2006) Drug delivery in the BME curricula. *Annals of Biomedical Engineering*, **34**, 270–275.
- 38 Tao, S.L., Papat, K. and Desai, T.A. (2006) Off-water fabrication and surface modification of asymmetric 3D SU-8 microparticles. *Nature Protocols*, **1**, 3153–3158.
- 39 Paasonen, L., Laaksonen, T., Johans, C., Yliperttula, M., Kontturi, K. and Urtili, A. (2007) Gold nanoparticles enable selective light induced drug release from liposomes. *Journal of Controlled Release*, **122**, 86–93.
- 40 Derfus, A.M., Von Maltzahn, G., Harris, T.J., Duza, T., Vecchio, K.S., Ruoslahti, E. and Bhatia, S.N. (2007) Remotely triggered release from magnetic nanoparticles. *Advanced Materials*, **19**, 3932–3936.
- 41 Kam, N.W.S., O'Connell, M., Wisdom, J.A. and Dai, H. (2005) Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. *Proceedings of the National Academy of Sciences of the United States of America*, **102**, 11600–11605.
- 42 West, J.L. and Halas, N.J. (2003) Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. *Annual Review of Biomedical Engineering*, **5**, 285–292.
- 43 Nishikawa, M., Takakura, Y. and Hashida, M. (2005) Theoretical considerations involving the pharmacokinetics of plasmid DNA. *Advanced Drug Delivery Reviews*, **57**, 675–688.

Index

2/4/A1 cell 137

a

ABC transporter 146, 203, 228ff.

– ABCB1, *see* MDR1 or P-glycoprotein

– ABCB11 290

– ABCC 244

– ABCC1, *see* multidrug resistance-related protein (MRP) family

– ABCC2 287

– ABCC3 291f.

– ABCC4 291f.

– ABCC5 292

– ABCC6 292

– ABCG2, *see* BCRP

– similarity to P-glycoprotein 498

Abraham descriptors 386

abraxane 601

absorption, *see also* ADME 34, 74f., 163ff., 528

– active 224ff.

– animal 167ff.

– carrier-mediated intestinal 199

– class II drug 35f.

– computational prediction 410ff.

– concentration dependence 144

– enhancement 582

– *ex vivo* method 169

– intestinal 187ff., 228

– number 34

– oral 413, 435

– phase 582

– model for prediction 174

– prediction 427

– simulation 454

– single-pass *in situ* 170

– solubility 145

absorption/permeability predictor 87

absorption rate 341

absorption rate constant 34

– effective 34

absorption scale factor (ASF) 476

absorptive intestinal transporter 245

ACAT, *see* advanced compartmental absorption and transit model

acetaminophen, *see* paracetamol

N-acetyltransferase, *see* NAT

α -acid glycoprotein (AGP) 119

adaptive fuzzy partitioning (AFP) 439

adefovir 293

ADME (absorption, distribution, metabolism, and excretion) 5, 73

ADME/PK

– determining parameter 169

– drug discovery 162ff.

– prediction 163

ADMET (absorption, distribution, metabolism, elimination/excretion, and toxicity)

modeling 378f.

– Predictor 457

– Risk 456ff., 472f.

advanced compartmental absorption and transit model (ACAT) 456ff., 475ff.

affinity 58, 248

– PEPT1 251

albendazole 42

alfentanil 344

allometry 176

allopurinol 281

Almond descriptors 383

amiloride 194

amino acid transporter 234

δ -amino levulinic acid 227, 247

amlodipine besilate 164

amoxicillin 194ff.

amphiphilicity 86f.

anhepatic phase 343

- animal
 - absorption 167ff.
 - relevance of animal model 174
- animal bioavailability
 - prediction 441
- antipyrene 195
- antitumor agent 564f.
- APC (*adenomatous polyposis coli*) 253
- apical side 362
- apparent permeability coefficient 142
- applicability domain (AD) 63, 396f.
- aquaporin 8 238
- aqueous solubility
 - definition 11
 - drug (table) 22
 - drug discovery 10ff.
 - hit identification (HI) 12
 - lead identification 18
 - lead optimization 18
- artificial neural network (ANN) 390, 439
- associative neural network (ASNN) 59
- atenolol 193ff.
- atorvastatin 164
- atovaquone 42
- ATP binding cassette (ABC) transporter, *see*
 - ABC transporter
- ATPase activity 513
- ATPase activity assay 500ff.
- AUC (area-under-the-curve) 3, 341
- 3'-azido-3'-deoxythymidine (AZT) 224ff., 293

- b**
- bacampicillin 339
- bacteria
 - intestinal 540
- Balaban index 379
- bambuterol 562f.
- base 82
- basolateral side 362
- Bayesian neural network (BNN) 83, 390
- Bayesian regularized neural network (BRNN) 60
- BCRP (breast cancer-resistance protein, ABCG2) 137, 186, 203, 236, 285ff., 365, 499, 526
 - mutation 304
- BCUT (Burden, Cas, University of Texas) descriptor 379
- Beer's law 106
- bicalutamide 24
- bile acid transporter 237
- bile salt 38
- biliary excretion 284
- binding 539
- bioavailability 1, 163ff., 186ff., 435
 - absolute 188f.
 - animal 167ff., 441
 - definition 1ff., 527f.
 - determining bioavailability 171
 - drug 334
 - *in silico* prediction 438ff.
 - local 598
 - nutrient 445
 - oral 1, 341, 437ff., 606
 - simulation 454, 481f.
 - systemic 598
- biopartitioning micellar chromatography (BMC) 85
- Biopharmaceutical Classification System (BCS) 34f., 190
 - application 524ff.
 - Class I drugs 35, 541
 - Class II drugs 36ff., 541
 - Class III drugs 36, 541
 - Class IV drugs 36, 541
 - permeability 190
 - redefining BCS solubility class boundary 43
 - regulatory aspect 541
 - solubility 190
- bioprecursors 566
- biorelevant media 41
- biosensor 86
- biowaiver extension potential 44
- Bjerrum plot 24
- blood-brain barrier (BBB) 80
- breast cancer-resistance protein, *see* BCRP
- Brij35 85
- BSA
 - absorption 145
- BSEP (bile salt export pump) 285ff., 308
- bumetanide 281
- butanilicaine 340

- c**
- Caco-2 cell 76ff., 120, 134ff.
 - active transport 145
 - cDNA expression 363
 - gene expression profiling 238ff.
 - metabolism study 146
 - quality control 143
 - standardization 143
- calculated log *P* (Clog *P*) 18, 83
- calculated molecular descriptor 377ff.
- calculated molecular properties 377ff.
- cancer 252ff.
 - colon 253

- GIT 256
 - candidate drug 12
 - capecitabine 563
 - capillary electrophoresis 114
 - carbamazepine 194
 - carbon, labeled (¹⁴C) 169
 - L-carnitine 225
 - carrier group 566
 - CART model 424
 - cassette dosing 171
 - CD147 255
 - CDH17 232, 257
 - CDX2 256f.
 - cefadroxil 246
 - cefazoline 582
 - cefixime 246
 - cell culture 134ff.
 - cell line
 - modified 360ff.
 - cell vector system 360f.
 - cell-based assay 121
 - central nervous system (CNS) 87
 - cephalexin 199, 227, 243ff., 367
 - CES 337ff.
 - chemoluminescent nitrogen detection (CLND) 17
 - chenodeoxycholic acid 227
 - Cheqsol 26, 110
 - chitosan glutamate 574
 - cholesterol 124
 - chromatographic hydrophobicity index (CHI) 83, 119
 - chromatographic method 122
 - ciliprolol 246
 - cimetidine 194
 - cisplatin 227
 - cladribine 234
 - Claritin 165
 - class II drug 36
 - Biopharmaceutics Classification System-based FDA guideline 43
 - biowaiver extension potential 44
 - dissolution 38
 - *in vitro* dissolution test 41
 - clearance (CL) 178, 295ff., 346, 437
 - biliary 300
 - total plasma 3
 - clopidogrel 564
 - colon 339, 583ff.
 - colon carcinogenesis 252f.
 - transporter 253
 - colonic water 586
 - comparative molecular field analysis (CoMFA) 250
 - comparative molecular similarity indices analysis (CoMSIA) 250
 - compartmental absorption and transit model (CAT) 455
 - competition
 - prediction 514
 - competition assay 508
 - computation
 - physicochemical property measurement 88
 - computational absorption prediction 410ff.
 - consensus method 395
 - concentration dependence
 - absorption 144
 - concentrative nucleoside transporter (CNT) 233
 - CNT1 243
 - constitutional descriptor 378
 - convex hull method 397
 - cosolvent mixture 112
 - creatinine 197
 - critical micelle concentration (CMC) 38, 600
 - Crohn's disease 589
 - CVODE 476
 - D-cycloserine 225ff.
 - cyclosporine 207, 224, 236, 246, 583
 - cytochrome P450 146, 189, 202ff., 336f.
 - CYP2C9 206, 336ff., 345
 - CYP3A4 146, 189ff., 202ff., 306f., 336ff., 583
 - CYP3A5 336
 - expression 363f.
 - metabolism 338, 484
 - cytotoxicity 565
- d**
- D-PAS 110
 - danazol 42
 - data
 - interpretation 126
 - presentation 126
 - set 419ff.
 - storage 126
 - degradation 539
 - luminal 539
 - delivery
 - buccal 574
 - lysosomal 604
 - modern strategy 571ff.
 - nanotechnological system 603ff.
 - oral 571ff.
 - self-assembled 600
 - tissue-selective 568
 - DEPT, *see* directed enzyme-prodrug therapy

- descriptors 58, 378ff.
 - 3D 381
 - absorption 410f.
 - Almond 383
 - constitutional 378
 - fragment- and functional group-based 378
 - hydrogen bonding 80
 - Jurs 382
 - quantitative prediction of oral absorption 419
 - qualitative prediction of oral absorption 420
 - topological 379
 - WHIM 381f.
 - desipramine 225
 - detection methodology 14ff.
 - chemoluminescent nitrogen detection (CLND) 17
 - turbidimetric method 14
 - UV absorption method 15
 - 1,2-dichloroethane (DCE)/water system 83
 - diffusion
 - paracellular passive 193
 - passive 80, 142
 - transcellular passive 196
 - digoxin 226ff., 246
 - dipyridamole 39
 - directed enzyme-prodrug therapy (DEPT) 567
 - dissociation constant 110
 - cosolvent mixture 112
 - measuring 111ff.
 - separation 113
 - dissolution 76, 528ff.
 - gastrointestinal 38ff.
 - *in vitro* test 41
 - number 34f.
 - testing requirement 552
 - volume 41
 - distance-based method 397
 - distribution, *see also* ADME 76
 - *in silico* estimation 481
 - volume 76, 437
 - distribution coefficient 81
 - DMSO 13f., 105, 117f.
 - aqueous solubility 10ff.
 - solubility assay 18
 - DNA 598ff.
 - donor 362
 - well 123f.
 - L-dopa 194ff.
 - dose 550
 - prediction in man 176f.
 - dose number 34f.
 - dosing 585
 - time 585
 - doxorubicin 236, 508
 - dried-down solution method 20
 - drug 2
 - active absorption 224ff.
 - active uptake (table) 479
 - bioavailability 334ff., 598ff.
 - candidates 12, 544
 - class II 36ff.
 - degradation 540
 - delivery 599ff.
 - development 481f., 543
 - discovery 102
 - efflux (table) 479
 - high-solubility 533ff.
 - intestinal transport and absorption 134ff.
 - low-solubility 546
 - metabolism 208
 - metabolism and pharmacokinetics (DMPK) 9, 73ff.
 - oral absorption 140
 - particle size 40
 - physicochemical property 73ff.
 - rule-based ranking (table) 459ff.
 - transport 208
 - transport assay 362
 - drug-drug-interaction 309
 - transporter-mediated 305
 - drug-likeness 87
 - drug-loading capacity 601
 - druggability 34, 456, 528
 - physicochemical approach 73ff.
 - DSSTox (distributed structure-searchable toxicity) database network 473
- e**
- effective absorption rate constant 34
 - effective intestinal permeability 535
 - efflux
 - mechanistic correction 478
 - protein 526
 - sinusoidal 290
 - transporter 236, 365
 - electromotive force (E, emf) 111
 - electrotopological state index 379
 - enalapril 194ff.
 - enalaprilate 194
 - endocytosis 604
 - endosome 604
 - ensemble method 395
 - enteric coating 539
 - enterocyte 191ff.
 - compartment 480

- Environmental Protection Agency (EPA) 473
- epithelial-mesenchymal transition (EMT) 252ff.
- equilibrative nucleoside transporter (ENT) 233
- ENT2 243
- erythromycin 281
- ESI mass spectrometry detection 122
- esophagus 573f.
- etoposide 226ff.
- ex vivo* method
- absorption 169
- excretion, *see* ADME
- extended release (ER) 538ff.
- f**
- familial adenomatous polyposis (FAP) 253
- FaSSIF (fasting-state simulated artificial intestinal fluid) 78
- FDA guideline
- Biopharmaceutics Classification System-based 43
- fed-state simulating intestinal fluid (FeSSIF) 42
- fenazon 194
- fexofenadine 194, 207
- fingerprint 378
- first-pass effect 572
- flow cytometry 109
- flow injection analysis (FIA) 109
- fludarabine 225ff.
- 5-fluorouracil 281, 563
- fluoxetine 164
- fluticasone propionate 56
- fluvastatin 194ff., 206f.
- food-drug interaction 549
- formulation
- nanotechnological 601
- formulation principle 545
- solid 545
- fraction absorbed 417
- fractional factorial design (FFD) 398
- fragment- and functional group-based descriptor 378
- free energy of binding 511
- furosemide 194ff.
- g**
- gas chromatography 113
- gastric emptying 579ff.
- gastric inhomogeneity 576
- GastroPlus program 55
- gastrointestinal (GI)
- characteristics 530
- dissolution 38ff.
- pH 39
- simulation 454f.
- transit 39
- gastrointestinal tract (GIT) 166, 185ff., 530f., 572
- lower 583ff.
- mid 576ff.
- transporter 223ff.
- upper 573ff.
- Gaussian process (GP) 60
- gemcitabine 225
- gene expression profiling 238
- general solvation equation 412
- genetic algorithms (GA) 394
- genetic programming 394f., 426
- algorithm 440
- genetic rule extraction (G-REX) 426
- genotype 242
- geometric method 397
- glucose 195f., 225
- glucose transporter 246
- GLUT2 232
- GLUT5 234
- sodium coupled (SGLT1) 246
- gluththaione S-transferase (GST) 208
- GRID probe 383
- grid-independent descriptor (GRIND) 510
- griseofulvin 43
- gut wall 335
- first-pass metabolism 347
- metabolism 334ff.
- h**
- half-life 438
- half-transporter 499
- halofantrine 43
- hCE-1 (human carboxylesterase 1) 147
- HDM (hexadecane membrane) 85
- Henderson-Hasselbalch relationship 82, 110
- hepatic efflux process 298
- hepatic intrinsic clearance 444
- hepatic portal vein cannulation 173
- hepatic transport 278ff.
- hepatic uptake 278f., 294f.
- hepatobiliary transport 299
- hereditary nonpolyposis colorectal cancer (HNPCC) 253
- hERG (human ether-a-go-go related gene) 474
- heuristic molecular lipophilicity potential (HMLP) 385
- high-throughput log $D_{7,4}$ measurement 117

- high-throughput log D_{pH} measurement 118
 high-throughput measurement 106ff.
 – physicochemical property 106ff.
 high-throughput screening (HTS) 102
 high-throughput solubility (HTSol) assay 14
 – kinetic 14
 – thermodynamic 14
 hit identification (HI) 12
 hit-to-lead stage 105, 428
 hologram QSAR (HQSAR) 440
 hPEPT1 199ff.
 HPT1 232f., 256f.
 HT29 cell 139
 human immunodeficiency virus (HIV)
 inhibitor 246
 human serum albumin (HSA) 119
 HYBOT descriptor 386
 hybrid potentiometric/UV spectrometric
 technique 112
 hydrochlortiazide 194
 hydrogen bond
 hydrogen bond acceptor (HBA) 413, 435, 511
 hydrogen bond donor (HBD) 413, 435,
 511
 hydrogen bonding 80
 hydrophobic surface property 382
 hydrophobicity 81
- i**
- ibuprofen 39
 IEC-18 cell 140
 immediate release (IR) 36
 immobilized artificial membrane (IAM)
 83ff., 119
 immobilized liposome chromatography
 (ILC) 85
in vitro – *in vivo* correlation (IVIVC) 41, 191,
 536, 547ff.
in vivo human permeability database 187
in vivo method
 – determining bioavailability 171
 in-house model 63
 inflammation 252
 inflammatory bowel disease (IBD) 259
 influenza 561f.
 inhalation 173
 inhomogeneity
 – gastric 576
 intestinal absorption 188f.
 – carrier mediated 199
 intestinal barrier permeation 512
 intestinal drug transport and absorption
 134ff.
 intestinal metabolism 342ff.
- intestinal mucosa
 – physiology 334
 – profiling 238
 intestinal perfusion technique 187ff.
 – *in vitro* 190
 intestinal permeability 134
 – effective 535
 intestinal stem cells 258
 intestinal transporters 242
 – absorptive 245
 intestine 238f., 339, 576
 – active transport 228
 – disease 251
 – transporter 251
 ion exchange chromatography 113
 ionization 78f., 413
 ionized form 79
 isocarboxamid 340
 isosbestic point 107
- j**
- jejunal transport 202f.
 Jurs descriptors 382
- k**
- k*-nearest neighbor (KNN) 59
 – modeling 392
 ketoconazole 39ff., 205ff.
 ketoprofen 39ff., 194
 Kier-Hall indices 379
- l**
- lansoprazole 164
 large neutral amino acid (LNAA) 201
 LAT1 244
 lazar (lazy structure-activity relationship)
 method 398
 lead generation phase 428
 lead identification (LI) 12ff.
 – thermodynamic solubility 26f.
 lead optimization (LO) 12ff., 428f.
 – thermodynamic solubility 26f.
 Leadscope fingerprint 378
 leave-multiple-out cross validation
 (LMO-CV) 399
 leave-on-one-out cross validation (LOO-CV)
 399
 L-leucine 197
 linear discriminant analysis (LDA) 392, 510
 linear method 388
 linear solvation energy relationship (LSER)
 58
 lipid bilayer 122
 lipid-DNA nanoparticulate 607

- Lipinski's rule-of-5, *see* rule-of-5
 Lipitor 164
 lipolysis model
 – dynamic 42
 lipophilicity 74ff., 115ff., 413
 – effective 82
 – intrinsic 81
 – measuring 116
 liposome 600ff.
 – partitioning 86
 liquid chromatography/mass spectrometry (LC/MS) 109, 122
 lisinopril 194ff.
 liver 189f., 335
 – basolateral membrane 293
 LLC-PK₁ cell 363
 local drug bioavailability
 – improved 606
 local model 65
 Loc-I-Gut® technique 187ff., 537f.
 log *D* 81
 – calculated 83
 log *P* (log₁₀ of water/octanol partition coefficient) 81, 385
 – calculated 18, 83
 – versus log *D*_{PH}
 loracarbef 247
 loratadine 165
 losartan 194ff.
 Losec 164
 lung 174
 lysophospholipid 603
- m**
 macromolar prodrugs 566
 Madin-Darby canine kidney (MDCK) cell 120, 136f.
 – cDNA expression 363
 Mahalanobis distance 63
 MATE (multidrug and toxic compound extrusion) 285ff.
 maximal absorbable dose (MAD) 77
 – calculation 55
 maximal recommended therapeutic dose (MRTD) 473f.
 MDR1 (multidrug resistance transporter), *see* P-glycoprotein
 medication
 – orally administered 571ff.
 melphalan 227, 244
 melting point (MP) 58
 membrane
 – artificial 83ff.
 – bile canalicular 308
 – composition 123
 – diffusion 196
 – HDM 85
 – permeability 84, 412
 – sinusoidal 305
 – transporter 242
 membrane barrier permeation 512
 membrane potential change 249
 metabolic enzymes 363
 metabolism, *see also* ADME 202, 442
 – drug 108
 – gut wall first-pass 347
 – hepatic first-pass 342
 – *in silico* estimation 484
 – intestinal 342ff.
 – presystemic 188f.
 – simulation 454
 – study 146
 methotrexate 281
 α-methyl dopa 194ff.
 metoprolol 194, 482
 micellar electrokinetic chromatography (MEKC) 85
 microemulsion electronic chromatography (MEEKC) 119
 microscopic analysis 22
 midazolam 482
 model 63ff.
 – 3D-QSAR pharmacophore 509f.
 – applicability domain 63
 – development 419
 – predictive *in silico* 508
 – validation 399
 modeling 484f.
 – QSAR 88
 modular binding approach 511
 molecular descriptor
 – 2D-based 377
 – calculated 377ff.
 molecular interaction field (MIF) 383
 molecular lipophilicity potential (MLP) 385
 molecular property
 – calculated 377ff.
 molecular lipophilicity potential (MLP) descriptor 83
 molecular size 79
 monocarboxylate transporter (MCT) 235, 526
 monosaccharide transporter 234
 montelukast 10
 mRNA expression profiling 240
 MRP, *see* multidrug resistance-related protein family
 mucosa 334ff.
 – buccal 574

- intestinal 334ff.
- multidrug resistance transporter, *see* MDR1
- multidrug resistance-related protein (MRP) family 136, 197, 526
- MRP1 (ABCC1) 186, 236, 292f., 365, 499
- MRP2 137ff., 236, 286ff., 304ff., 361ff.
- MRP3 186, 236, 291
- MRP4 291f.
- MRP5 292f.
- MRP6 292f.
- multiple indicator dilution (MID) method 294
- multiple linear regression (MLR) 59, 388, 439
- multivariate statistical analysis 387ff.

n

- nanocarrier
 - single-molecule-based 601
- nanocrystal 599
- nanoparticulate
 - biological stability 602
 - processed 601f.
 - self-assembling 600
- nanosystem 606
 - improved oral drug bioavailability 606
- nanotechnological formulation
 - pharmaceutical property 601
- nanotechnology 597ff.
 - delivery 603ff.
- naproxen 194
- NAT (N-acetyltransferase) 340
- nephelometer 109
- nephelometric detection 14
- neuraminidase inhibitors 561f.
- neutral forms 79
- neutral species 115
- new chemical entity (NCE) 245
- nifedipine 25, 364, 574
- non-polar surface area (NPSA) 413
- non-steroidal anti-inflammatory drugs (NSAID) 43
- nonsink analysis 142
- Norvasc 164
- Noyes-Whitney model 38, 529
 - Nernst-Brunner and Levich modification 38
- NTCP (Na⁺ taurocholate cotransporting polypeptide) 278ff., 308
- nucleoside transporter
 - concentrative (CNT) 233
 - equilibrative (ENT) 233
- nutrient
 - bioavailability 445
 - nutrient absorption carrier 551

o

- OAT, *see* organic anion transporter
- OATP, *see* organic anion transporting peptide
- octanol/water distribution coefficient 83
- OCT, *see* organic cation transporter
- Ogast/OgastORO 164
- Oie-Tozer equation 76
- olanzapine 165
- omeprazole 164, 539
- onion design (OD) 398
- oral absorption 436ff.
 - computational model 413
 - definition 436
 - improved 606
 - qualitative prediction 420ff.
 - quantitative prediction 413ff.
- oral bioavailability, *see* bioavailability
- ordinary differential equation (ODE) 474
- organic anion transporter (OAT) 281ff.
- organic anion transporting polypeptide (OATP) 235, 278ff.
 - OATP1A2 281, 367
 - OATP1B1 137, 278ff., 301ff., 365
- organic cation transporter (OCT) 201f., 235, 284
 - OCNT1 201f., 235
 - OCNT2 201f., 235
- oseltamivir 562
- OST α/β 292

p

- p53 253
- P-glycoprotein (P-gp, ABCB1, MDR1) 81, 136ff., 186, 196ff., 203, 254, 286ff., 361ff.
 - ATPase activity assay 500f.
 - function 500
 - mutation 301
 - similarity to other ABC transporter 498f.
 - structure-activity relationship 498ff.
- paclitaxel 226ff., 246, 281
- paracellular passive diffusion 193
- paracetamol 578
- parallel artificial membrane permeation/permeability assay (PAMPA) 75, 84, 120ff.
 - calculation of permeability 124
 - gastrointestinal 123
 - *in silico* 85
 - paroxetine 165
- partial least squares (PLS) 61, 389
- partition coefficients 176

- partitioning method 393
 - PASS 87
 - passive flux 507
 - PAT1 234
 - peptide transporter 232f.
 - PEPT1 147, 199, 224ff., 247ff., 259f., 367, 526, 551
 - PEPT2 367
 - prediction of affinity 251
 - percentage absorbed 480
 - perfusion method 170
 - permeability 34, 74f., 84ff., 119ff., 442
 - apical-to-basolateral 122
 - apparent 125
 - apparent permeability coefficient 142
 - basolateral-to-apical 122
 - calculation from PAMPA data 124
 - effective 125
 - *in vitro* model 84
 - *in vivo* 537
 - *in vivo* study 185ff.
 - intestinal 134
 - jejunal 206
 - membrane 84
 - pathophysiological effect 589
 - surface property 126
 - pH
 - absorption 144
 - gut 589
 - partition hypothesis 455
 - pharmaceutical objectives 560
 - pharmacodynamic objectives 564
 - pharmacodynamic (PD) processes 3
 - pharmacodynamics 525
 - pharmacokinetic model
 - physiological 177
 - pharmacokinetic objective 561
 - pharmacokinetic (PK) processes 2f.
 - pharmacokinetics 74, 437, 525
 - physiologically based 176
 - pharmacophore fingerprint 384
 - pharmacophore models
 - 3D-QSAR 509f.
 - phloridzin 246
 - phosphatidylcholine 124
 - phosphatidylethanolamine 124
 - phosphatidylinositol 124
 - phosphatidylserine 124
 - physicochemical factor 34
 - physicochemical parameter 531
 - physicochemical property
 - high-throughput measurement 106ff.
 - physicochemical property measurement
 - computation 88
 - physicochemical screening 102ff.
 - high-throughput profiling 104
 - physiological modeling 443
 - physiological parameter 531
 - physiologically-based pharmacokinetic (PBPK) 78, 310
 - *in silico* estimation of distribution 481
 - modeling 86, 444
 - plasma concentration 178
 - plasma protein
 - binding 76
 - polar surface area (PSA) 58, 80, 386, 413
 - polarity 413
 - polarized light microscopy (PLM) 22
 - positron emission tomography (PET) 310
 - potassium channels 474
 - potentiometry 24
 - powder X-ray diffraction (PXRD) 22
 - pravastatin 225ff., 283
 - precipitate detection 109
 - prediction
 - animal bioavailability 441
 - hepatic efflux process 298
 - *in silico* prediction of human bioavailability 434ff.
 - prodrug 559ff.
 - strategy 560
 - type 565f.
 - progesterone 43
 - property-based descriptor 385
 - propranolol 194, 482
 - Prozac 164
 - pSol 24
 - public model 63
- q**
- quality by design (QbD) 552
 - quantitative structure-activity relationships (QSAR) 66, 400
 - 3D-QSAR pharmacophore models 509f.
 - combinatorial 88
 - binding of drugs to transporter 249
 - descriptors 66
 - *in silico* QSAR model of oral bioavailability 438
 - modeling 88
 - quantitative structure-property relationships (QSPR) 56
- r**
- radiolabel 169
 - Raman microscopy 22
 - ramipril 339
 - range-based method 397

- ranitidine 194, 281
 - ranking
 - rule-based (table) 459ff.
 - receiver 362
 - well 123f.
 - receiver-operating characteristic (ROC)
 - curve 425
 - relative activity factor (RAF) 295
 - reversed-phase high-performance liquid chromatography (RP-HPLC) 81, 113ff.
 - RNA
 - siRNA 598
 - root mean square error of predictions (RMSE) 59
 - rotating-disk method 529
 - rule extraction
 - genetic programming-based 426
 - rule-based method 393f.
 - rule-based ranking (table) 459ff.
 - rule-of-5 87, 435, 512
- S**
- saquinavir 482
 - semisimultaneous dosing 172
 - Seroxat 165
 - sertraline 165
 - SGLT1 246
 - shake-flask method 22, 104
 - log $D_{7,4}$ 117
 - shape 79, 413
 - simulated gastric fluid (SGF) 42
 - simulation 454ff., 484f.
 - mechanistic 474
 - simvastatin 164, 339
 - single-nucleotide polymorphism (SNP) 242
 - single-pass *in situ* absorption 170
 - single-photon emission computed tomography (SPECT) 310
 - sink condition 125, 191, 534
 - binding-maintained 125
 - ionization-maintained 125
 - physically-maintained 125
 - siRNA 598
 - size descriptor 79
 - calculated 79
 - SLC, *see* solute carrier family
 - small intestinal transit pattern 581
 - sodium decanoate 582
 - soft drug 560
 - soft independent modelling of class analogy (SIMCA) 440
 - software for aqueous solubility 61
 - solid
 - solubility 21
 - supernatant concentration method 109
 - state characterization 22
 - solubility 54, 76f., 104ff., 412, 528
 - absorption 145
 - aqueous, *see* aqueous solubility
 - calculated 78
 - DMSO-based 18
 - dried-down solution method 20
 - high-throughput (HTSol) 14
 - *in silico* prediction 54ff.
 - *in vivo* 550
 - intrinsic 24
 - kinetic 104
 - measuring 104ff.
 - method 104ff.
 - modeling 56ff.
 - pH range 107
 - potentiometry 24
 - rate (SR) 531
 - solid 21f.
 - thermodynamic 22ff., 104
 - solute carrier (SLC) family 228ff., 254
 - SLC2A2 232
 - SLC10A1 279
 - SLC15A1 224ff., 243
 - SLC19 254
 - SLC22 281ff.
 - SLC28A1 232
 - SLC29A1 232
 - SLC31A1 254
 - SLC38A 254
 - SLC47A1 290
 - SLC5A1 232
 - SLC5A8 255
 - SLCO 278f.
 - SLCO1B1, *see also* OATP1B1 301ff.
 - systematic nomenclature 278
 - static method 169
 - statistical method 387ff.
 - stem cells
 - intestinal 258
 - stomach 339, 572ff.
 - structure-activity relationships (SAR) 400, 509
 - P-glycoprotein 498
 - substrate-transporter affinity 504
 - substrate-transporter interactions 503f.
 - sucralfate 575
 - sulfotransferase (SULT) 337ff.
 - supernatant concentration 106ff.

- support vector machine (SVM) 59, 390f., 425
- surface plasmon resonance (SPR) technology 86
- t**
- tacrolimus 226ff.
- talinolol 226ff.
- target factor analysis (TFA) 112
- targeting
- intracellular 604
- tenofovir 293
- terbutaline 195f., 563
- test set selection 398
- tetracycline 281
- theophylline 281
- thermodynamic solubility 22ff.
- application in LI and LO 26f.
- thin-layer chromatography (TLC) system 81
- tight junction 199, 607
- tirapazamine 564f.
- tissue barrier 603
- TMF (transport, metabolism, and blood flow) 346
- 4-toluenesulfonylureido-carnosine 227, 248
- topological descriptors 379ff.
- TOPS-MODE method 423
- total plasma clearance 3
- toxicity, *see also* ADMET 567
- database 473
- toxicology 598
- training set 398
- transcellular passive diffusion 196
- transepithelial electrical resistance (TEER) 477
- Transil 86
- transit 581ff.
- colonic 584f.
 - pathophysiological effect 587
- translocation 248
- transport 186ff., 208
- active 301
 - apparent 513
 - assay 506
 - hepatobiliary 294
 - intrinsic 513
 - jejunal 202f.
 - rate 504
- transport experiment 141
- active 145, 478
- transporters
- ABC 146, 203, 228ff.
 - amino acid 234
 - ATP-complex 502
 - bile acid 237
 - colon cancer 253
 - drug absorption targeting 245
 - efflux 365f.
 - expression 365
 - gastrointestinal tract (GIT) 223ff.
 - intestinal 242
 - large neutral amino acid (LNAA) 201
 - monocarboxylate (MCT) 235
 - monosaccharide 234
 - nucleoside 233
 - organic anion 235
 - organic cation 235
 - overall hepatic uptake 295
 - peptide 232f.
 - tumor suppressor 255
 - uptake 367
- tritium (³H) 169
- troglitazone 42
- tumor stroma interaction 255
- tumor suppressor gene 255
- turbidimetric method 14
- turbidity measurement 109
- u**
- UDP-glucuronosyltransferase (UGT) 337ff.
- UGT1A1 208, 337
- unstirred water layer (UWL) 85, 121ff., 196
- uptake 309
- active 479
 - transporter 367
- urea 197
- Ussing diffusion chamber 345
- UV absorption method 15
- UV spectrometric technique 112
- v**
- valaciclovir (valacyclovir) 224, 246, 367
- valganciclovir 246
- valproic acid 235
- verapamil 194ff., 225
- vigabatrin 225ff.
- villus 335
- visualization
- on-the-fly 107
- VolSurf descriptors 383
- volume
- distribution 437
 - model for prediction 175

w

WHIM (weighted holistic invariant molecular)
descriptors 381f.
Wiener index 379
World Drug Indices (WDI) 87

y

Yalkowsky equation 58
Yasuda-Shedlovsky technique 113

z

Zagreb indices 379
zanamivir 561f.
zidovudine 281, 293
Zocor 164
Zoloft 165
Zyprexa 165